Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
17
Recruiting, any sponsor type, condition "transthyretin"
By trial status
The same filters, counted in each status. Pick one to switch.
17 trials
Showing 1 to 17, recently updated first.
Eidos Therapeutics, a BridgeBio companyIndustry
NCT07695701 · 150 participants (planned) · Start Jul 28, 2026 · Primary completion Aug 2030
Drug: Acoramidis (AG10) oral tablet · For: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM); Amyloidosis; Amyloid Cardiomyopathy and 1 more
Sites: Baltimore, Maryland; St Louis, Missouri; Philadelphia, Pennsylvania · 9 sites in all
- TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With PolyneuropathyPivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07223203 · 125 participants (planned) · Start Feb 3, 2026 · Primary completion Dec 27, 2027
Drug: Nucresiran; Vutrisiran · For: Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN
Sites: Aurora, Colorado; Chicago, Illinois; Baltimore, Maryland · 61 sites in all
- TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyPivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07052903 · 2,250 participants (planned) · Start Jul 2, 2025 · Primary completion May 28, 2030
Drug: Nucresiran; Sterile Normal Saline (0.9% NaCl) · For: Transthyretin Amyloidosis With Cardiomyopathy
Sites: La Jolla, California; Laguna Hills, California; Stanford, California · 267 sites in all
BayerBayer (BAYRY)
NCT07298044 · 50 participants (planned) · Start Feb 13, 2026 · Primary completion Sep 17, 2027
Drug: Acoramidis · For: Transthyretin Amyloid Cardiomyopathy
Sites: Sankt Pölten, Austria; Vienna, Austria; Braunau am Inn, Austria · 26 sites in all
- MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)Pivotal-lookingRecruiting
Intellia TherapeuticsIndustry
NCT06128629 · 1,200 participants (planned) · Start Dec 13, 2023 · Primary completion Dec 2027
Drug: NTLA-2001; Placebo · For: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Sites: Tucson, Arizona; Los Angeles, California; Palo Alto, California · 138 sites in all
- CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07207811 · 1,280 participants (planned) · Start Oct 2, 2025 · Primary completion Jun 29, 2029
Drug: NNC6019-0001; Placebo (NNC6019-0001) · For: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 299 sites in all
BayerBayer (BAYRY)
NCT07235462 · 2,000 participants (planned) · Start Oct 29, 2025 · Primary completion Apr 30, 2028
Drug: Acoramidis (356 mg film-coated tablets) · For: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Sites: Multiple Locations, Austria; Multiple Locations, Belgium; Multiple Locations, Croatia · 17 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06465810 · 1,850 participants (planned) · Start Jun 25, 2024 · Primary completion Dec 31, 2031
Drug: Treatment of transthyretin (ATTR) amyloidosis in observational study setting · For: Transthyretin Amyloidosis; ATTR-CM; ATTRv-PN and 3 more
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 89 sites in all
BayerBayer (BAYRY)
NCT07791160 · 500 participants (planned) · Start Sep 7, 2026 · Primary completion Dec 31, 2028
Drug: Acoramidis · For: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Sites: Many Locations, France
Nantes University HospitalAcademic, hospital or other
NCT07549841 · 40 participants (planned) · Start Sep 9, 2026 · Primary completion Oct 2027
Drug: [68Ga]Ga-FAPI-46 · For: Transthyretin Cardiac Amyloidosis
Sites: Nantes, France
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPivotal-lookingRecruiting
Eidos Therapeutics, a BridgeBio companyIndustry
NCT06563895 · 587 participants (planned) · Start May 12, 2025 · Primary completion Oct 2031
Drug: Acoramidis; Placebo oral tablet · For: Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis and 3 more
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 104 sites in all
Steen Hvitfeldt PoulsenAcademic, hospital or other
NCT06318260 · 15 participants (planned) · Start Apr 8, 2024 · Primary completion Jul 2026
Drug: Dobutrex · For: ATTR Amyloidosis Wild Type
Sites: Aarhus, Denmark
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07448623 · 14 participants (planned) · Start Mar 2, 2026 · Primary completion May 30, 2027
Drug: Coramitug · For: Transthyretin Amyloid Cardiomyopathy
Sites: Groningen, Netherlands
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT07306949 · 200 participants (planned) · Start Oct 1, 2025 · Primary completion Mar 31, 2028
Drug: Acoramidis · For: Transthyretin-type Cardiac Amyloidosis
Sites: Bunkyō City, Japan; Kumamoto, Japan; Kurume-shi, Japan · 16 sites in all
Qilu Pharmaceutical Co., Ltd.Industry
NCT06940336 · 15 participants (planned) · Start Jun 19, 2025 · Primary completion Jan 2028
Drug: Tafamidis Meglumine Soft Capsules · For: Transthyretin Amyloid Polyneuropathy
Sites: Jinan, China
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sAcademic, hospital or other
NCT06634108 · 20 participants (planned) · Start Sep 27, 2024 · Primary completion Sep 1, 2025
Drug: Genistein · For: Amyloid Cardiomyopathy
Sites: London, Canada
Zhejiang UniversityAcademic, hospital or other
NCT06082050 · 7 participants (planned) · Start Nov 2, 2023 · Primary completion Jul 3, 2025
Drug: YOLT-201 · For: Transthyroxin Amyloidosis Cardiomyopathy
Sites: Hangzhou, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.